Riociguat
Educational summary, not a formulary. Dosing is quoted from the Makindo chapters and topics site. The other sections are draft summaries not yet checked line by line against the BNF or SPC. Check dose, indication, interactions and monitoring in the BNF entry for Riociguat and local guidelines before prescribing.
sGC stimulator
Mechanism
Soluble guanylate cyclase stimulator.
Uses
Pulmonary arterial hypertension, chronic thromboembolic pulmonary hypertension.
Dosing
No dose is given in the chapters. See the BNF.
Side effects
Hypotension, headache, dyspepsia, haemoptysis.
Interactions
Nitrates and PDE5 inhibitors contraindicated.
Contraindications and cautions
Pregnancy, nitrates
Monitoring
BP
Pregnancy and breastfeeding
Contraindicated
Renal and hepatic impairment
Avoid in severe renal impairment
Overdose and reversal
Supportive
Special advice
Smoking reduces levels.
More from the textbook: uses, cautions and other points
- PAH is treated only in specialist centres: ERAs, PDE5 inhibitors, riociguat, prostacyclin drugs. Avoid pregnancy; never combine PDE5 inhibitors with nitrates.
Respiratory: Pulmonary Vascular Disease - Treatment — lifelong anticoagulation; pulmonary endarterectomy (potentially curative — specialist centre: Royal Papworth in the UK); balloon pulmonary angioplasty; riociguat for inoperable disease.
Cardiology: Venous Thromboembolism and Pulmonary Vascular Disease - Management — treat the underlying cause (groups 2 and 3); oxygen if hypoxic; diuretics; refer suspected PAH or CTEPH to a specialist centre; PAH-specific drugs (endothelin receptor antagonists, PDE5 inhibitors, prostanoids, riociguat; calcium channel blockers only for vasoreactive patients) — not interchangeable with treatment for …
Cardiology: Venous Thromboembolism and Pulmonary Vascular Disease - Nitric oxide pathway - PDE5 inhibitors (sildenafil, tadalafil - never with nitrates ; headache, flushing); riociguat (soluble guanylate cyclase stimulator - also for CTEPH; don't combine with PDE5 inhibitors).
Respiratory: Anatomy, Physiology and Pharmacology - Riociguat (a soluble guanylate cyclase stimulator) for inoperable or residual disease.
Respiratory: Pulmonary Vascular Disease - Soluble guanylate cyclase stimulator - riociguat (not with PDE5 inhibitors).
Respiratory: Pulmonary Vascular Disease - Riociguat | Inoperable or residual CTEPH, and PAH (specialist); not with PDE5 inhibitors or nitrates.
Respiratory: Pulmonary Vascular Disease - Pulmonary arterial hypertension - endothelin receptor antagonists (bosentan, ambrisentan, macitentan), PDE5 inhibitors (sildenafil, tadalafil), riociguat, prostacyclin analogues (iloprost, epoprostenol, selexipag); oxygen, diuretics, anticoagulation in some (see the Respiratory chapters).
Rheumatology: Connective tissue diseases
Where it is discussed in the book
- Cardiology: Venous Thromboembolism and Pulmonary Vascular Disease (2 mentions)
- Respiratory: Anatomy, Physiology and Pharmacology (1 mention)
- Respiratory: Pulmonary Vascular Disease (4 mentions)
- Respiratory: Sleep and Breathing (Complete) (1 mention)
- Rheumatology: Connective tissue diseases (1 mention)
- Integrated respiratory chapter (4 mentions)